Berman Jonathan
Office of Clinical and Regulatory Affairs, National Center For Complementary and Alternative Medicine, National Institutes of Health, 6707 Democracy Boulevard, Suite 401, Bethesda, MD 20892, USA.
Curr Infect Dis Rep. 2005 Jan;7(1):33-38. doi: 10.1007/s11908-005-0021-1.
The outbreaks of cutaneous disease caused by Leishmania tropica in Afghan refugees, visceral disease in Sudanese refugees, and cutaneous disease caused by Leishmania major in American forces in Iraq are examples of the large number of cases of leishmaniasis that can result when naive human populations intrude into regions where transmission is endemic. Injections of pentavalent antimony for 20 to 30 days have been the standard treatment for all forms of leishmaniasis, but resistance is growing and antimonials have moderate toxicity. Two major advances in the treatment of visceral leishmaniasis have been made in the past few years. Liposomal amphotericin B cures virtually all patients, with little side effects. Miltefosine is the first oral agent that is effective. For cutaneous disease, alternatives to antimony have been effective in certain regions but have not yet been generally evaluated.
热带利什曼原虫引起的阿富汗难民皮肤疾病、苏丹难民内脏疾病以及伊拉克美军中硕大利什曼原虫引起的皮肤疾病暴发,都是当缺乏免疫力的人群进入疾病传播流行地区时可能导致大量利什曼病病例的例子。注射五价锑20至30天一直是治疗所有形式利什曼病的标准方法,但耐药性在增加,且锑剂有中度毒性。过去几年,内脏利什曼病的治疗取得了两大进展。脂质体两性霉素B几乎能治愈所有患者,且副作用很小。米替福新是第一种有效的口服药物。对于皮肤疾病,在某些地区,锑剂的替代药物已显示有效,但尚未进行全面评估。